1. Clinical and Survival Impact of FDG PET in Patients with Suspicion of Recurrent Ovarian Cancer: A 6-Year Follow-Up
   Daniela Rusu et al, 2015, Front. Med. CrossRef
2. An update on the role of PET/CT and PET/MRI in ovarian cancer
   Benjapa Khiewvan et al, 2017, Eur J Nucl Med Mol Imaging CrossRef
3. Sarcoidosis manifesting as hepatic and splenic nodules mimicking ovarian cancer metastases: A case report
   YOSHIKUNI YONENAGA et al, 2015 CrossRef
4. An update on post-treatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncology (SGO) recommendations
   Ritu Salani et al, 2017, Gynecologic Oncology CrossRef
5. Detecting recurrent ovarian cancer: revisit the values of whole-body CT and serum CA 125 levels
   Pieh-Hsu Wang et al, 2019, Acta Radiol CrossRef
6. null
   Neeta Pandit-Taskar et al, 2016 CrossRef
7. Methylation-mediated repression of MiR-424/503 cluster promotes proliferation and migration of ovarian cancer cells through targeting the hub gene KIF23
   Tong Li et al, 2019, Cell Cycle CrossRef
8. Prospective assessment of 18F-FDG PET/CT in detection of recurrent ovarian cancer
   Ghada K. Gouhar et al, 2013, The Egyptian Journal of Radiology and Nuclear Medicine CrossRef
9. Usefulness of PET–CT in the evaluation of suspected recurrent ovarian carcinoma
   Mona Abdel Ghaffar ElHariri et al, 2019, Egypt J Radiol Nucl Med CrossRef
10. Metabolic shifts toward glutamine regulate tumor growth, invasion and bioenergetics in ovarian cancer.
    Lifeng Yang et al, 2014, Mol Syst Biol CrossRef
11. Which imaging technique should we use in the follow up of gynaecological cancer?
    Antonia Carla Testa et al, 2014, Best Practice & Research Clinical Obstetrics & Gynaecology CrossRef
12. Diagnostic performance of 18F-FDG PET/contrast-enhanced CT versus contrast-enhanced CT alone for post-treatment detection of ovarian malignancy
    Ahmed Tawakol et al, 2016, Nuclear Medicine Communications CrossRef
13. Nuclear medicine for imaging of epithelial ovarian cancer
    Seyed Mohammad Abedi et al, 2016, Future Oncology CrossRef
14. Whole-body diffusion-weighted magnetic resonance imaging in the diagnosis of recurrent ovarian cancer: a clinical feasibility study
    Katrijn L M Michielsen et al, 2016, BJR CrossRef
15. Diagnostic value of positron emission tomography (PET) and PET/computed tomography in recurrent/metastatic ovarian cancer: A meta-analysis
    Bo Xu et al, 2017, J. Obstet. Gynaecol. Res. CrossRef
16. PET/MR Imaging in Gynecologic Oncology
    Michael A. Ohliger et al, 2017, Magnetic Resonance Imaging Clinics of North America CrossRef
17. null
    Neeta Pandit-Taskar et al, 2017 CrossRef
18. The Value of PET-CT in Ovarian Epithelial Carcinoma: A Population-Based Study in British Columbia, Canada
    Sarah Aurelia Cook et al, 2020, Journal of Medical Imaging and Radiation Sciences CrossRef
19. N-acetylaspartate release by glutaminolytic ovarian cancer cells sustains protumoral macrophages.
    Alessio Menga et al, 2021, EMBO Rep CrossRef
20. The role of CT, PET-CT, and MRI in ovarian cancer
    Maurits Peter Engbersen et al, 2021, BJR CrossRef
21. null
    Neeta Pandit-Taskar et al, 2022 CrossRef
22. Role of 18F FDG PET/CT in evaluation of post-operative ovarian carcinoma
    Marwa Ibrahim El-Sayed Amer et al, 2022, Egypt J Radiol Nucl Med CrossRef
23. null
    Neeta Pandit-Taskar et al, 2022 CrossRef
24. 18F-FDG PET/MRI and 18F-FDG PET/CT for the Management of Gynecological Malignancies: A Comprehensive Review of the Literature
    Leila Allahqoli et al, 2023, J. Imaging CrossRef
25. Isolated metastases in soft tissue of the chest wall in ovarian cancer: case report
    I. V Kolyadina et al, 2013, Russian Journal of Oncology CrossRef
26. Role of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in the detection of recurrence and peritoneal metastasis from ovarian cancer in correlation with cancer antigen-125 tumor marker levels
    Ghada Ali Elsayed et al, 2024, Egypt J Radiol Nucl Med CrossRef